NIH Funding, Research Productivity, and Scientific Impact: a 20-Year Study

NIH Funding, Research Productivity, and Scientific Impact: a 20-Year Study

The paper addresses the problems of admissibility of human embryo analysis and the authorized safety to be acknowledged, in gentle of the rising significance that scientific analysis has been gaining within the medical and biomedical fields of embryonic stem cells for therapeutic functions. As for human embryo experimentation, notably on cryopreserved supernumerary embryos, European laws varies, for the reason that European Court docket has granted member States a large margin of appreciation.

Some nations, together with Italy, have strict laws defending embryos from the fertilisation stage, whereas others have taken permissive approaches, permitting experimentation till 14 days after fertilisation. Science, nevertheless, has proven that the 14-day restrict may be moved. The creator finds it mandatory to realize broad worldwide consensus and shared laws. Lawmakers, nevertheless, must stability respect for the precept of life, represented by the embryo, towards scientific wants, in an effort to devise sound laws safeguarding each apparently conflicting basic values.

The Analysis Challenge Grant (R01) is the oldest grant mechanism utilized by the Nationwide Institutes of Well being (NIH). Receiving an R01 award is usually taken as an indication of scientific success. We introduced normative information on a number of productiveness and impression metrics for a extra goal evaluation of funded grants’ scientific success.  All preliminary R01 grants awarded by NIH within the 12 months 2000 had been prospectively adopted and evaluated utilizing the numbers of publications and citations, in addition to the h-indices on the grant degree. We examined the variability, time traits, and relations amongst these metrics to raised perceive the funded tasks’ cumulative output and impression.

Introducing Key Components Relating to Entry to Private Information for Scientific Analysis within the Perspective of Growing Revolutionary Medicines

This text goals at opening discussions and selling future analysis about key components that must be taken under consideration when contemplating new methods to organise entry to non-public information for scientific analysis within the perspective of creating revolutionary medicines. It supplies an summary of those key components: the alternative ways of accessing information, the speculation of the important services, the Regulation on the Free Move of Non-personal Information, the Directive on Open Information and the re-use of public sector data, and the Basic Information Safety Regulation (GDPR) guidelines on accessing private information for scientific analysis.

Within the perspective of fostering analysis, selling revolutionary medicines, and having all of the uncooked information centralised in huge databases localised in Europe, we advise to additional examine the likelihood to search out acceptable and balanced options with full respect of basic rights, in addition to for personal life and information safety. These embrace utilizing open science platforms, pre-registering research, making certain reproducible analyses, utilizing high-powered research, making certain open entry to analysis supplies and merchandise, and conducting replication research.

Suicide analysis is vitally vital, yet-like psychology analysis extra broadly-faces methodological challenges. In recent times, researchers have raised considerations about customary practices in psychological analysis, considerations that apply to suicide analysis and lift questions on its robustness and validity. Within the current paper, we evaluate these considerations and the corresponding options put forth by the “open science” neighborhood.

We construct upon current guides, deal with particular obstacles confronted by suicide researchers, and supply a transparent set of beneficial practices for suicide researchers. Specifically, we contemplate challenges that suicide researchers could face in searching for to undertake “open science” practices (e.g., prioritizing massive samples) and recommend attainable methods that the sector could use in an effort to guarantee strong and clear analysis, regardless of these challenges.

NIH Funding, Research Productivity, and Scientific Impact: a 20-Year Study

Enhancing open and rigorous science: ten key future analysis alternatives associated to rigor, reproducibility, and transparency in scientific analysis

As a part of a coordinated effort to broaden analysis exercise round rigor, reproducibility, and transparency (RRT) throughout scientific disciplines, a crew of investigators on the Indiana College Faculty of Public Well being-Bloomington hosted a workshop in October 2019 with worldwide leaders to debate key alternatives for RRT analysis.

The workshop aimed to establish analysis priorities and alternatives associated to RRT.  Over two-days, workshop attendees gave displays and took part in three working teams: (1) Enhancing Training & Coaching in RRT, (2) Lowering Statistical Errors and Rising Analytic Transparency, and (3) Wanting Outward: Rising Truthfulness and Accuracy of Analysis Communications. Following small-group discussions, the working teams introduced their findings, and contributors mentioned the analysis alternatives recognized. The investigators compiled an inventory of analysis priorities, which had been circulated to all contributors for suggestions.

100bp DNA Marker

20-abx098052
  • EUR 272.00
  • EUR 189.00
  • 2.5 ml
  • 500 ul

Molecular Weight Marker

abx098957-15ul 15 ul
EUR 105

100bp DNA Marker

D1100-050 50㎍
EUR 165

100bp DNA Marker

D1100-250 5X50㎍
EUR 550

1Kb DNA Marker

D1101-050 50㎍
EUR 131

1Kb DNA Marker

D1101-250 5X50㎍
EUR 300

Oligodendrocyte Marker O1

MO15001 50 ug
EUR 331

Oligodendrocyte Marker O4

MO15002 50 ug
EUR 337

KP Marker Plus

KPM-1 12 Pen(s)
EUR 117

DL5000 DNA Marker

MD102-01 250 μl
EUR 107

DL5000 DNA Marker

MD102-02 500 μl
EUR 113

DL15000 DNA Marker

MD103-01 250 μl
EUR 109

DL15000 DNA Marker

MD103-02 500 μl
EUR 115

Myeloid Cell Marker (Macrophage / Granulocyte Marker); Clone BM-1 (Concentrate)

RA0400-C.1 0.1 ml
EUR 125

Myeloid Cell Marker (Macrophage / Granulocyte Marker); Clone BM-1 (Concentrate)

RA0400-C.5 0.5 ml
EUR 300

CMV-Luciferase (No marker)

LVP911a 1x107 IFU/ml x 200ul
EUR 349
Description: Pre-made lentivirus express firefly luciferase under CMV promoter (do not containing any antibiotic selection marker), provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

EF1a-Luciferase (No marker)

LVP911b 1x107 IFU/ml x 200ul
EUR 349
Description: Pre-made lentivirus express firefly luciferase under EF1a promoter (do not containing any antibiotic selection marker), provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

1Kb Plus DNA Marker

20-abx098051
  • EUR 300.00
  • EUR 203.00
  • 2.5 ml
  • 500 ul

Histiocytoma Marker(D11) Antibody

BNCA0348-250 250uL
EUR 383
Description: Primary antibody against Histiocytoma Marker(D11), APC conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNCA0719-250 250uL
EUR 383
Description: Primary antibody against Mitochondrial Marker(MTC719), APC conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC02) Antibody

BNCA0740-250 250uL
EUR 383
Description: Primary antibody against Mitochondrial Marker(MTC02), APC conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC754) Antibody

BNCA0754-250 250uL
EUR 383
Description: Primary antibody against Mitochondrial Marker(MTC754), APC conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody

BNCA0894-250 250uL
EUR 383
Description: Primary antibody against Melanoma Marker(PNL2), APC conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNCAP0348-100 100uL
EUR 199
Description: Primary antibody against Histiocytoma Marker(D11), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNCAP0348-500 500uL
EUR 544
Description: Primary antibody against Histiocytoma Marker(D11), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNCAP0719-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC719), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNCAP0719-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC719), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC02) Antibody

BNCAP0740-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC02), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC02) Antibody

BNCAP0740-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC02), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC754) Antibody

BNCAP0754-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC754), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC754) Antibody

BNCAP0754-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC754), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody

BNCAP0894-100 100uL
EUR 199
Description: Primary antibody against Melanoma Marker(PNL2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody

BNCAP0894-500 500uL
EUR 544
Description: Primary antibody against Melanoma Marker(PNL2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNC810348-100 100uL
EUR 199
Description: Primary antibody against Histiocytoma Marker(D11), CF680R conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNC810348-500 500uL
EUR 544
Description: Primary antibody against Histiocytoma Marker(D11), CF680R conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNC810719-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC719), CF680R conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNC810719-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC719), CF680R conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC02) Antibody

BNC810740-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC02), CF680R conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC02) Antibody

BNC810740-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC02), CF680R conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC754) Antibody

BNC810754-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC754), CF680R conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC754) Antibody

BNC810754-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC754), CF680R conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody

BNC810894-100 100uL
EUR 199
Description: Primary antibody against Melanoma Marker(PNL2), CF680R conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody

BNC810894-500 500uL
EUR 544
Description: Primary antibody against Melanoma Marker(PNL2), CF680R conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNC880348-100 100uL
EUR 199
Description: Primary antibody against Histiocytoma Marker(D11), CF488A conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNC880348-500 500uL
EUR 544
Description: Primary antibody against Histiocytoma Marker(D11), CF488A conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNC880719-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC719), CF488A conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNC880719-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC719), CF488A conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNCB0348-100 100uL
EUR 199
Description: Primary antibody against Histiocytoma Marker(D11), Biotin conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNCB0348-500 500uL
EUR 544
Description: Primary antibody against Histiocytoma Marker(D11), Biotin conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNCB0719-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC719), Biotin conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNCB0719-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC719), Biotin conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC02) Antibody

BNCB0740-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC02), Biotin conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC02) Antibody

BNCB0740-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC02), Biotin conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC754) Antibody

BNCB0754-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC754), Biotin conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC754) Antibody

BNCB0754-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC754), Biotin conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody

BNCB0894-100 100uL
EUR 199
Description: Primary antibody against Melanoma Marker(PNL2), Biotin conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody

BNCB0894-500 500uL
EUR 544
Description: Primary antibody against Melanoma Marker(PNL2), Biotin conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNC550348-100 100uL
EUR 199
Description: Primary antibody against Histiocytoma Marker(D11), CF555 conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNC550348-500 500uL
EUR 544
Description: Primary antibody against Histiocytoma Marker(D11), CF555 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNC550719-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC719), CF555 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNC550719-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC719), CF555 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC02) Antibody

BNC550740-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC02), CF555 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC02) Antibody

BNC550740-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC02), CF555 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC754) Antibody

BNC550754-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC754), CF555 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC754) Antibody

BNC550754-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC754), CF555 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody

BNC550894-100 100uL
EUR 199
Description: Primary antibody against Melanoma Marker(PNL2), CF555 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody

BNC550894-500 500uL
EUR 544
Description: Primary antibody against Melanoma Marker(PNL2), CF555 conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNC430348-100 100uL
EUR 199
Description: Primary antibody against Histiocytoma Marker(D11), CF543 conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNC430348-500 500uL
EUR 544
Description: Primary antibody against Histiocytoma Marker(D11), CF543 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNC430719-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC719), CF543 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNC430719-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC719), CF543 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC02) Antibody

BNC430740-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC02), CF543 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC02) Antibody

BNC430740-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC02), CF543 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC754) Antibody

BNC430754-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC754), CF543 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC754) Antibody

BNC430754-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC754), CF543 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody

BNC430894-100 100uL
EUR 199
Description: Primary antibody against Melanoma Marker(PNL2), CF543 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody

BNC430894-500 500uL
EUR 544
Description: Primary antibody against Melanoma Marker(PNL2), CF543 conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNC470348-100 100uL
EUR 199
Description: Primary antibody against Histiocytoma Marker(D11), CF647 conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNC470348-500 500uL
EUR 544
Description: Primary antibody against Histiocytoma Marker(D11), CF647 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNC470719-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC719), CF647 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNC470719-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC719), CF647 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC02) Antibody

BNC470740-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC02), CF647 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC02) Antibody

BNC470740-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC02), CF647 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC754) Antibody

BNC470754-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC754), CF647 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC754) Antibody

BNC470754-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC754), CF647 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody

BNC470894-100 100uL
EUR 199
Description: Primary antibody against Melanoma Marker(PNL2), CF647 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody

BNC470894-500 500uL
EUR 544
Description: Primary antibody against Melanoma Marker(PNL2), CF647 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC02) Antibody

BNC880740-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC02), CF488A conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC02) Antibody

BNC880740-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC02), CF488A conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC754) Antibody

BNC880754-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC754), CF488A conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC754) Antibody

BNC880754-500 500uL
EUR 544
Description: Primary antibody against Mitochondrial Marker(MTC754), CF488A conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody

BNC880894-100 100uL
EUR 199
Description: Primary antibody against Melanoma Marker(PNL2), CF488A conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody

BNC880894-500 500uL
EUR 544
Description: Primary antibody against Melanoma Marker(PNL2), CF488A conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNC940348-100 100uL
EUR 199
Description: Primary antibody against Histiocytoma Marker(D11), CF594 conjugate, Concentration: 0.1mg/mL

Histiocytoma Marker(D11) Antibody

BNC940348-500 500uL
EUR 544
Description: Primary antibody against Histiocytoma Marker(D11), CF594 conjugate, Concentration: 0.1mg/mL

Mitochondrial Marker(MTC719) Antibody

BNC940719-100 100uL
EUR 199
Description: Primary antibody against Mitochondrial Marker(MTC719), CF594 conjugate, Concentration: 0.1mg/mL

Members recognized the next precedence analysis questions: (1) Can RRT-focused statistics and mathematical modeling programs enhance statistics apply?; (2) Can specialised coaching in scientific writing enhance transparency?; (3) Does modality (e.g. nose to nose, on-line) have an effect on the efficacy RRT-related schooling?; (4) How can automated packages assist establish errors extra effectively?; 

What’s the prevalence and impression of errors in scientific publications (e.g., analytic inconsistencies, statistical errors, and different goal errors)?; (6) Do error prevention workflows cut back errors?; (7) How can we encourage post-publication error correction?; (8) How does ‘spin’ in analysis communication have an effect on stakeholder understanding and use of analysis proof?; (9) Do instruments to assist writing analysis studies enhance comprehensiveness and readability of analysis studies?; and (10) Is it attainable to inculcate scientific values and norms associated to truthful, rigorous, correct, and complete scientific reporting? Members recognized vital and comparatively unexplored questions associated to bettering RRT. This record could also be helpful to the scientific neighborhood and investigators searching for to advance meta-science (i.e. analysis on analysis).

From laboratory bench to benchmark: technology transfer in laboratory medicine.

From laboratory bench to benchmark: technology transfer in laboratory medicine.

Life Sciences research, improve the innovation, able to influence clinical decision making, both in diagnosis and therapy. Indeed, from the knowledge of the special needs and demands of the technical-scientific, researchers were able to contain and experiment innovative solutions. Despite these strengths, transferring research to the market in the Life Sciences shows criticalities enough.

The purpose of this paper is to provide concrete evidence of the technology transfer process based on the exploitation of the results obtained by KronosDNAsrl, an academic spin-off focusing on reproductive medicine.


method
Different tools are used to evaluate the technical feasibility (validation of the results obtained with the prototype) and to manage the process of technology transfer from One4Two®.


result
Different analyzes we conducted demonstrated the feasibility of the proposed solution. As a result, a prototype has been developed and validated One4Two®.


conclusion
Here, we provide evidence of how the power of knowledge acquired translational research on the “bench” can be used to transfer to the market on a “benchmark” allows innovation in Laboratory Medicine. In addition, the model described for One4Two® can be easily transferred to other products.

From laboratory bench to benchmark: technology transfer in laboratory medicine.
From laboratory bench to benchmark: technology transfer in laboratory medicine.

Scientific integrity among nursing students participating in the Scientific Initiation Program: An exploratory study.

To determine the position and practice adopted by nursing students in scientific initiation program on the principles of scientific integrity in various stages of the process of doing science.An quantitative exploratory study, in which participants from the nursing students Scientific Initiation Program of the federal District interviewed.

Fifty (50) nursing students participated in the study. Most participants were interviewed presented a good understanding of the process of doing research in different stages. However, it was found that although they were familiar with the practices of good science, students do not always behave in the most responsible way.

It was observed that the knowledge on topics related to the ethics of the scientific process is mainly obtained through formal education, which consists of classes and courses. Nevertheless, the importance of complementary spaces such as study and research groups recognized.

Conclusion: Research experience that education and vocational training room are important for students. Hence, good research practice need to be incorporated at the beginning of the academic curriculum.